PET-CT in clinical oncology

Clinical and Translational Oncology

Volumn 9, Issue 8, 2007, Pages 494-505

  Maldonado, Antonio ^a,c   Gonzalez Alenda F J ^a   Alonso, M ^b   Sierra, J M ^b  

^a Centro PET Recoletas La Milagrosa   (Spain)

^b Centro PET Recoletas   (Spain)

^c Grupo Recoletas   (Spain)

Author keywords

Cancer; Diagnosis; FDG; Metabolism; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GOLD STANDARD; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; SARCOMA; SENSITIVITY AND SPECIFICITY; THYROID CANCER; TREATMENT PLANNING; UROGENITAL TRACT CANCER; BREAST TUMOR; HEAD AND NECK TUMOR; LUNG TUMOR; NEOPLASM; RADIOGRAPHY; REVIEW; SCINTISCANNING; THYROID TUMOR; UROGENITAL TRACT TUMOR;

BREAST NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; UROGENITAL NEOPLASMS;

EID: 38449090705     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0093-5     Document Type: Article

References (59)

1. Townsend DW (2001) A combined PET/CT scanner: The choices. J Nucl Med 42:533-534
2. Czernin J, Dahlbom M, Ratib O et al (2004) Introduction. In: Czernin J, Dahlbom M, Ratib O, Schiepers C (eds) Atlas of PET/CT imaging in oncology. Springer-Verlag, Berlin, Heidelberg
3. Rodríguez M, Asensio C, Maldonado A et al (2004) PET-TAC: Indicaciones, revisión sistemática y meta-análisis. Informe de la Agencia de Evaluación de Tecnologías Sanitarias N o 41. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Madrid, June
4. Andradas E, Reza M, Gómez N et al (2004) Efectividad, seguridad e indicaciones del sistema híbrido PET/TAC. Informe Técnico IT01/2004. Unidad de Evaluación de Tecnologías Sanitarias. Agencia Laín Entralgo. October
5. Rodríguez M, Asensio C (2005) Uso Tutelado de la PET con FDG. Ministerio de Sanidad y Consumo. Instituto de Salud Carlos III. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Madrid, November. ISBN: 84-95463-30-X
6. 18 F-FDG PET/CT. J Nucl Med 44:1267-1270
7. Zimmer L, Snyderman CH, Fukui M et al (2005) The use of combined PET/CT for localizing recurrent head and neck cancer: The Pittsburgh experience. Ear Nose Throat J 84:108-110
8. Branstetter BF IV, Blodgett TM, Zimmer LA et al (2005) Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 235:580-586
9. Schöder H, Yeung HWD, Gonen M et al (2004) Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231:65-72
10. Gordin A, Daitzchman M, Doweck I et al (2006) Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: Diagnostic accuracy and impact on clinical management. Laryngoscope 116:273-278
11. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47:755-762
12. Chen Y, Su C, Ding H et al (2006) Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res 26:1471-1477
13. Nahas Z, Goldenberg D, Fakhry C et al (2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115:237-243
14. Palmedo H, Bucerius J, Joe A et al (2006) Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management. J Nucl Med 47:616-624
15. Gould MK, Maclean CC, Kuschner WG et al (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914-924
16. Petkovska I, Shah SK, McNitt-Gray MF et al (2006) Pulmonary nodule characterization: A comparison of conventional with quantitative and visual semi-quantitative analyses using contrast enhancement maps. Eur J Radiol 59:244-252
17. Yi CA, Lee KS, Kim B-T et al (2006) Tissue characterization of solitary pulmonary nodule: Comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 47:443-450
18. McKenna R, Libshitz H, Mountain C, McMurtey M (1985) Roentgenographic evaluation of mediastinal lymph nodes for pre-operative assessment in lung cancer. Chest 88:206-210
19. Dwamena B, Sonnad S, Angobaldo J, Wahl R (1999) Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology 213:530-536
20. Lardinois D, Weder W, Hany T et al (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507
21. Antoch G, Stattaus J, Nemat A et al (2003) Nonsmall cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229:526-533
22. Halpern BS, Schiepers C, Weber WA et al (2005) Presurgical staging of non-small cell lung cancer: Positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128:2289-2297
23. Shim SS, Lee KS, Kim B-T et al (2005) Nonsmall cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236:1011-1019
24. Keidar Z, Haim N, Guralnik L et al (2004) PET/CT using 18 F-FDG in suspected lung cancer recurrence: Diagnostic value and impact on patient management. J Nucl Med 45:1640-1646
25. Lardinois D, Weder W, Roudas M et al (2005) Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 23:6846-6853
26. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23:8362-8370
27. De Leyn P, Stroobants S, De Wever W et al (2006) Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: A Leuven Lung Cancer Group study. J Clin Oncol 24: 3333-3339
28. 18 F-fluoro-2-deoxy-D-glucosepositron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12:97-106
29. Cerfolio RJ, Bryant AS, Ojha B (2006) Restaging patients with N2 (stage IIIa) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg 131:1229-1235
30. 18] fluoro-dglucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7:369-376
31. Tatsumi M, Cohade C, Mourtzikos KA et al (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33:254-262
32. Bar-Shalom R, Guralnik L, Tsalic M et al (2005) The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32:918-924
33. Yuan S, Yu Y, Chao KSC et al (2006) Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47:1255-1259
34. 18] fluoro-d-glucose positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol 8:193-200
35. Cohade C, Osman M, Leal J, Wahl R (2003) Direct comparison of 18 F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44:1797-1803
36. Kamel IR, Cohade C, Neyman E et al (2004) Incremental value of CT in PET/ CT of patients with colorectal carcinoma. Abdom Imaging 29:663-668
37. 18F-FDG PET, inline PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 46:587-595
38. Votrubova J, Belohlavek O, Jaruskova M et al (2006) The role of FDG-PET/ CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 33:779-784
39. Even-Sapir E, Parag Y, Lerman H et al (2004) Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232:815-822
40. Selzner M, Hany TF, Wildbrett P et al (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240: 1027-1034
41. 18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 86:194-199
42. Heinrich S, Goerres GW, Schafer M et al (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235-243
43. Petrowsky H, Wildbrett P, Husarik DB et al (2006) Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 45:43-50
44. 18 FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020
45. Goerres GW, Stupp R, Barghouth G et al (2005) The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: longterm outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32:153-162
46. Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357-365
47. 18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6:411-416
48. Freudenberg LS, Antoch G, Schatt P et al (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31:325-329
49. Schaefer NG, Hany TF, Taverna C et al (2004) Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 232:823-829
50. Tatsumi M, Cohade C, Nakamoto Y et al (2005) Direct comparison of FDG PET and CT findings in patients with lymphoma: Initial experience. Radiology 237:1038-1045
51. Schaefer NG, Strobel K, Taverna C, Hany TF (2007) Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34:60-67
52. Sironi S, Buda A, Picchio M et al (2005) Lymph node metastasis in patients with clinical earlystage cervical cancer: Detection with integrated FDG PET/CT. Radiology 238:272-279
53. Hauth E, Antoch G, Stattaus J et al (2005) Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 56:263-268
54. Sironi S, Messa C, Mangili G et al (2004) Integrated FDG PET/CT in patients with persistent ovarian cancer: Correlation with histologic findings. Radiology 233:433-440
55. 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 46:1460-1465
56. 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 24: 1178-1187
57. Gutzeit A, Antoch G, Kuhl H et al (2005) Unknown primary tumors: detection with dualmodality PET/CT - initial experience. Radiology 234:227-234
58. Nanni C, Rubello D, Castellucci P et al (2005) Role of FDG PET/CT imaging for the detection of an unknown primary tumor: Preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 32:589-592
59. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 27:795-802